TSC1 and neoplasm: Our study elucidates a specific ERS-dependent anti-tumor mechanism of GSK-J4 in <i>Tsc</i>-deficient contexts and demonstrates the synergistic efficacy of combining epigenetic and mTORC1 inhibitors.